日本語 
Kura Oncology, Inc., and Kyowa Kirin Co., Ltd. announced Kura submitted a New Drug Application (NDA) for ziftomenib, a highly selective, once-daily, oral, investigational menin inhibitor, for the treatment of…
Latest News
Re-air Raises ¥580M for Vascular Regeneration Therapy
Tokyo biotech startup Reair Inc., which spun out from Juntendo University, has…
NKGen and HekaBio team up on NK Cell therapy in Japan
NKGen Biotech, Inc. is a clinical-stage biotech firm. They focus on NK…
BlueMeme Invests in MediVally for Medical Innovation
BlueMeme Partners Inc., a group company of BlueMeme Inc., is pleased to…
Theoria Launches Brain Health Media ‘Nourabo’
Theoria Technologies Inc. has released a new media called "No Labo" that…
Elix, LINC Launch First AI Drug Platform with Fed Learning
Elix, Inc. and the Life Intelligence Consortium (LINC) have launched the world’s…
Fujitsu and Acer Medical pilot AI for Gait-based health risk
Fujitsu Limited and Acer Medical Inc., a leader in AI-driven medical imaging…
Quantum Biology: Japan’s Role in the Next Medical Frontier
For many years, Japan has been a world leader in precision, innovation,…
ELYZA Develops Japan-Focused Medical LLM Platform
ELYZA Inc., which promotes the social implementation of large-scale language models (LLMs),…
Latest Article
English